For Industry

EuroPOND’s work promotes the use of cutting-edge data-science techniques in the fight against dementia and neurological disease. For industry groups involved in the testing of putative treatments, we provide two advances to current practice:

  1. Most clinical trials to date use a single outcome measure as a primary end-point. Our models fuse information from multiple biological markers into a patient staging system that has the potential to provide much greater sensitivity to treatment effect.
  2. Our models can provide new staging systems that enable high-resolution patient stratification. This will help to avoid the heterogeneity in patient cohorts that is a major cause of the failure of 99% of clinical trials on Alzheimer’s Disease treatments to date.

Contact us for further information.